Daily Newsletter

13 November 2023

Daily Newsletter

13 November 2023

Mirati’s lung cancer treatment gains EMA CHMP’s positive opinion

An oral small-molecule KRASG12C inhibitor, Krazati penetrates the central nervous system.

Vishnu Priyan November 13 2023

Mirati Therapeutics has obtained a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine Agency for Krazati (adagrasib) to treat KRASᴳ¹²ᶜ-mutated advanced non-small cell lung cancer (NSCLC).

Krazati is indicated for usage as a targeted therapy option in patients with a minimum of one previous systemic therapy whose disease advanced following treatment.

An oral small-molecule KRASᴳ¹²ᶜ inhibitor, Krazati penetrates the central nervous system.

It recently received accelerated approval (Subpart H) from the US Food and Drug Administration (FDA).

In early November 2023, Krazati received conditional marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA).

This therapy is currently being analysed as a single agent and with other anti-cancer treatments for advanced KRASᴳ¹²ᶜ-mutated solid tumours, including NSCLC, pancreatic and colorectal cancers.

The open-label Phase I/II KRYSTAL-1 trial is assessing adagrasib alone or as a combination regimen for advanced KRASᴳ¹²ᶜ-mutated solid tumours.

Mirati Therapeutics chief medical officer Alan Sandler stated: “The positive opinion from the CHMP for Krazati marks an important step on the path to providing access to a potentially best-in-class therapeutic option to patients living with this difficult-to-treat disease.

“We look forward to approval from the European Commission and the opportunity to positively impact the lives of eligible patients living in the European Union.”

Disease-modifying therapies (DMTs) entering the PD market pose significant opportunities and risks

As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs. However, the lack of validated predictive biomarkers of PD progression have made the development of DMTs and neuroprotective agents challenging.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close